Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | AR | P10275 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466270 | 0.86 | AR (0.63) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL6468391 | 0.85 | ALDH1A1 (0.57) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL6469507 | 0.85 | KMT2A (0.52) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL6464376 | 0.85 | KMT2A (0.51) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL5361685 | 0.85 | KMT2A (0.51) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL4922469 | 0.84 | KMT2A (0.51) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL6464084 | 0.84 | LMNA (0.64) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL4918939 | 0.84 | KMT2A (0.48) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL24411089 | 0.82 | KMT2A (0.47) | ALDH1A1KMT2APOLBLMNAMEN1 | |
| SCHEMBL6467825 | 0.82 | KMT2A (0.47) | ALDH1A1KMT2APOLBLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022098544-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220144809-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1466902-A1 | ANDROGEN RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144809-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AND ASSOCIATED METHODS OF USE | AR, ADRM1, CRBN | ALDH1A1 1867/4885KMT2A 1886/4885POLB 2720/4885 |
| US-20050101657-A1 | Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative | SHBG, PRLHR, FSHR | ALDH1A1 2144/4885KMT2A 2015/4885POLB 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.